We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravitreal Bevacizumab for Diabetic Macular Edema

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Isfahan Ophthalmology Research Center.
Recruitment status was:  Enrolling by invitation
Sponsor:
ClinicalTrials.gov Identifier:
NCT00703235
First Posted: June 23, 2008
Last Update Posted: June 23, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Isfahan Ophthalmology Research Center
  Purpose

Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.

This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.


Condition Intervention Phase
Macular Edema Diabetic Retinopathy Drug: Bevacizumab Phase 2 Phase 3

Study Type: Interventional

Resource links provided by NLM:


Further study details as provided by Isfahan Ophthalmology Research Center:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetes mellitus
  • Clinically significant macular edema
  • Possibility of performing macular OCT
  • Consent of patient for inclusion in the study

Exclusion Criteria:

  • History of macular photocoagulation in less than 6 months of inclusion in the study
  • Necessity of surgical intervention
  • Rejection of the remaining in the study by patient
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT00703235     History of Changes
Other Study ID Numbers: MUI - clinical - 185290
First Submitted: June 20, 2008
First Posted: June 23, 2008
Last Update Posted: June 23, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Edema
Macular Edema
Diabetic Retinopathy
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents